

Le Malattie Infettive emergenti e riemergenti: una sfida globale e il ruolo della risposta nazionale

Prof. Massimo Andreoni

Professore Emerito di Malattie Infettive

Università Tor Vergata, Roma

Direttore Scientifico Società italiana Malattie Infettive

Consiglio Superiore di Sanità



Ministero della Salute
Consiglio Superiore di Sanità

Disclosures

I have received funding for membership of Advisory Boards, for the preparation of educational materials, for research and educational grants, for membership of speaker panels and for support for travel to conferences from the following companies:

- Gilead Sciences
- Viiv Healthcare
- Abbvie
- Pfizer
- GSK
- Menarini
- Moderna
- Astra Zeneca

Antimicrobial resistance

TBC, AIDS, Malaria

COVID,

.....Pandemic Flu ??????????


Not if....but WHEN

Pandemics are inevitable

They recur at more-or-less cyclical intervals

Timeline of twenty-first-century viral outbreaks, from 2000 to the present day.

Viral strains and the area of outbreak are indicated along with the timeline




2022 → **Vaccine derived Poliovirus** – Indonesia, Algeria **EBOLA** – Uganda, rep. Dem. Congo
MERS – Arabia Saudita **H5N1** – Spagna **DENGUE**- Nepal, Pakistan, Uganda
Rift Valley Fever – Mauritania **Marburg** – Ghana **Monkeypox**-Americas Europe

2023 → **Morbillo**– Sudan **EBOLA** – Uganda **MERS** – Oman **H5N1** – Ecuador
Vaccine derived Poliovirus – Sudan **Yellow fever**– AFRICA



Infectious disease in an era of global change

The global international air travel network expanded substantially from 1933 to 2020 (data from [WorldPop](#)).




(Recent) increasing connectivity

The total number of airline passengers doubled from just below two billion in 2000 to more than four billion in 2019




Population projections in 2010 and relative population change projected until 2100

(source NASA Socioeconomic Data and Applications Center).



Anno	Popolazione/mondo (miliardi)	
1804	1,0	123 aa
1900	1,6	
1927	2	
1950	2,5	48 aa
1960	3,032	
1970	3,690	
1980	4,442	40 aa
1990	5,293	
2000	6,144	
2010	6,970	
2020	7,821	
2050	9,7	
2080	10,4	


Population by world Region, 1800-2100 (millions)






Infectious disease in an era of global change


Rapid rates of urbanization in low-income and middle-income countries, and the increase in populations residing in crowded, low-quality dwellings, have created new opportunities for the emergence of infectious diseases



Novel viral sharing events coincide with population centers




Human population density



In 2070 human population centers in equatorial Africa, south China and southeast Asia will overlap with projected hotspots of cross-species viral transmission in wildlife.






Spillover of highly pathogenic avian influenza H5N1 virus to dairy cattle

The highly pathogenic avian influenza (HPAI) H5N1 virus clade 2.3.4.4b has caused the death of millions of domestic birds and thousands of wild birds in the USA since January 2022. Throughout this outbreak, spillovers to mammals have been frequently documented.

70 cases
1 death
(CFR: 1.4%)

Model of spillover and spread of the HPAI H5N1 genotype B3.13



Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2015

Country	2003-2009*		2010		2011		2012		2013		2014		2015		Total	
	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths	cases	deaths
Azerbaijan	8	5										0	0	0	8	5
Bangladesh	1	0										0	0	0	7	1
Cambodia	9	7									4	0	0	56	37	
Canada	0	0									0	0	0	1	1	
China	38	25									0	5	1	52	31	
Djibouti	1	0									0	0	0	1	0	
Egypt	90	27									14	136	39	346	116	
Indonesia	162	134									2	2	2	199	167	
Iraq	3	2									0	0	0	3	2	
Lao People's Democratic Republic	2	2									0	0	0	2	2	
Myanmar	1	0									0	0	0	1	0	
Nigeria	1	1									0	0	0	1	1	
Pakistan	3	1									0	0	0	3	1	
Thailand	25	17									0	0	0	25	17	
Turkey	12	4									0	0	0	12	4	
Viet Nam	112	57	7	2	0	0	4	2	2	1	2	2	0	0	127	64
Total	468	282	48	24	62	34	32	20	39	25	52	22	143	42	844	449

H5N1
844 cases
449 deaths
53% mortality rate

* 2003-2009 total figures. Breakdowns by year available on next table

Total number of cases includes number of deaths
 WHO reports only laboratory cases
 All dates refer to onset of illness



The NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JANUARY 27, 2005

VOL. 352 NO. 4

Probable Person-to-Person Transmission of Avian Influenza A (H5N1)


Kumnuan Ungchusak, M.D., M.P.H., Prasert Auewarakul, M.D., Scott F. Dowell, M.D., M.P.H.,
Rungrueng Kitphati, M.D., Wattana Auwanit, Ph.D., Pilaipan Puthavathana, Ph.D., Mongkol Uiprasertkul, M.D.,
Kobporn Boonnak, M.Sc., Chakrarat Pittayawonganon, M.D., Nancy J. Cox, Ph.D., Sherif R. Zaki, M.D., Ph.D.,
Pranee Thawatsupha, M.S., Malinee Chittaganpitch, B.Sc., Rotjana Khontong, M.D.,
James M. Simmerman, R.N., M.S., and Supamit Chunsutthiwat, M.D., M.P.H.

La mutazione PB2-E627K, trovata recentemente in isolati umani
aumenta l'efficienza polimerasica e il rischio di trasmissibilità
interumana




CLIMATE
CHANGE


The global mean temperature in 2023 is estimated to have been 1.54 ± 0.06 °C (2.77 ± 0.11 °F) above the average temperature from 1850-1900, a period often used as a pre-industrial baseline for global temperature targets.



Land and Ocean Temperatures 1850-2023




Temperature anomalies relative to 1850-1900 average and 95% confidence intervals
Land data from Berkeley Earth, ocean data adapted from HadSST after interpolation
Temperature anomalies for sea ice regions are calculated separately and not shown



Climate change will drive novel cross-species viral transmission

Between 10,000 and 600,000 species of mammal virus are estimated to have the potential to spread in human populations, but the vast majority are currently circulating in wildlife, largely undescribed and undetected by disease outbreak surveillance.


We map potential hotspots of viral sharing, using a phylogeographic model of the mammal-virus network, and projections of geographic range shifts for 3,870 mammal species under climate change and land use scenarios for the year 2070.




Climate change will drive novel cross-species viral transmission

**The mammal-virus network.
The present-day viral sharing network by mammal order inferred from modeled pairwise predictions of viral sharing probabilities. The expected number of shared viruses with most sharing existing among the most species and closely-related groups.**

Nodes are sized by total number of species in that order in the host-virus association dataset, color is scaled by degree.



The impact of increasing temperatures due to climate change on infectious diseases





The nightmare Oziem Turkmen Recem (Izmir, Turkiye)

The 2020 report of the *Lancet* Countdown on health and climate change: responding to converging crises

Change in climate suitability for infectious diseases

Solid lines represent the annual change.


Dashed lines represent the trend since 1950 for malaria



World Health Organization

2024 Malaria World Report

Average of months suitable for malaria transmission



N. Watts. Lancet 2021; 397: 129–70



In 2023, malaria caused **262 million** clinical episodes and **597K** deaths.




76% of all deaths in Africa were among children aged under **5** years in 2023.



CLIMATE CHANGE AND COMMUNICABLE DISEASES

Tracking infectious diseases in a warming world

Mathematical models of dengue vectorial capacity for *A aegypti* and *A albopictus* mosquitoes reveal temporal changes in the potential for dengue transmission due to a warming climate since 1950.



In 2015-2019 global climate suitability for the transmission of dengue increased by 8.9% for *Aedes aegypti* and 15.0% for *Aedes albopictus*.




The Perpetual Challenge of Infectious Diseases

Factors involved in infectious disease emergence

- ⑩ Human demographics and behaviour
- ⑩ Economic development and land use
- ⑩ War (intent to harm) and famine, poverty and social inequality
- ⑩ International trade and commerce
- ⑩ Human susceptibility to infection
- ⑩ Breakdown of public-health measures (lack of political will)
- ⑩ Technology and industry
- ⑩ Microbial adaptation
- ⑩ Changing ecosystems, climate and weather


Advance planning and preparedness are critical to help reduce the impact of a pandemic

Figure 1. The continuum of pandemic phases^a



^a This continuum is according to a "global average" of cases, over time, based on continued risk assessment and consistent with the broader emergency risk management continuum.

Modello di corrispondenza tra le fasi pandemiche e le fasi operative proposto dall'OMS



Imagining the future of pandemics and epidemics

A 2022 perspective



Categories

Pathogen and host characteristics

Public health and social measures

Contextual factors

Categories

Key factors


Pathogen and host characteristics

Transmissibility

Variant diversity and susceptibility to vaccines

Human immunity and vulnerability levels

Symptom range and mortality rate



S: Susceptible

I: Infected

R: Recovered


β : transmission rate

γ : recovered rate

Categories


Key factors

Public health and social measures



Categories

Key factors



[Home](#) > [Infectious disease topics](#) > [Related public health topics](#)

Vaccine hesitancy



TECHNICAL REPORT

**Catalogue of interventions
addressing vaccine hesitancy**




Spike protein-encoded mRNA

SARS-CoV-2 trimero della proteina spike




SARS-CoV-2 spike protein trimer



Proteine Virali spike

Cytosol

Ribosoma



Golgi

Reticolo Endoplasmatico

Nucleo

THE NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE 2023




Katalin Karikó e Drew Weissman

Monoclonal Antibody Evolution


Immunogenicity

e.g. ibritumomab




Highly immunogenic
100% Mouse

e.g. rituximab and abciximab




Still immunogenic
~30% Mouse

e.g. trastuzumab and bevacizumab



Still immunogenic
~5-10% Mouse


e.g. adalimumab and panitumumab



Least immunogenic

- Mouse variable
- Mouse constant
- Human variable
- Human constant

Nobel Prize in Physiology or Medicine 1984




Niels K. Jeme, Georges Kohler and César Milstein
Nobel Prize in 1984 for the development of monoclonal antibodies.

Fully Mouse 1st generation Chimeric 2nd generation Humanised 3rd generation "Fully" Human 4th generation



Screaming out loud J. Kluytmans (Utrecht, Netherlands)

What makes people distrust science?



Piano strategico operativo di preparazione e risposta ad una pandemia da patogeni a trasmissione respiratoria a maggiore potenziale pandemico 2025-2029


Obiettivi

Rafforzare la preparazione a livello nazionale e locale per affrontare una futura pandemia da agenti patogeni respiratori.

- **Obiettivo 1:** ridurre la trasmissione, la morbilità e la mortalità.
- **Obiettivo 2:** coordinamento a livello nazionale e locale delle emergenze
- **Obiettivo 3:** ridurre l'impatto della pandemia sui servizi sanitari e sociali
- **Obiettivo 4:** tutelare la salute degli operatori sanitari
- **Obiettivo 5:** informare, coinvolgere e responsabilizzare la comunità

"Every day a pandemic doesn't happen is another day we have to prepare.

Michael Osterholm





TOR VERGATA
UNIVERSITÀ DEGLI STUDI DI ROMA

TOR VERGATA
UNIVERSITÀ DEGLI STUDI DI ROMA



09/12/2025

